UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035766
Receipt number R000040717
Scientific Title Effect of the supplement on accommodation of the eye in middle- and old-aged adults: A randomized, double blinded, placebo controlled, and parallel group comparison study.
Date of disclosure of the study information 2019/02/04
Last modified on 2020/02/04 10:12:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of the supplement on accommodation of the eye in middle- and old-aged adults: A randomized, double blinded, placebo controlled, and parallel group comparison study.

Acronym

Effect of the supplement on accommodation of the eye in middle- and old-aged adults

Scientific Title

Effect of the supplement on accommodation of the eye in middle- and old-aged adults: A randomized, double blinded, placebo controlled, and parallel group comparison study.

Scientific Title:Acronym

Effect of the supplement on accommodation of the eye in middle- and old-aged adults

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of the supplement on accommodation of the eye in middle- and old-aged adults after administration of the supplement for 4 weeks.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Accommodation of the eye

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingestion of the test food for 4 weeks

Interventions/Control_2

Ingestion of the placebo for 4 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Japanese male and female aged 35 to 65 years old at the time of the informed consent.
2. Subject who has no eye diseases other than refractive error (dysregulation).
3. Subject whose naked vision for each eye is more than 0.2.
4. Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.

Key exclusion criteria

1. Subject who is taking medication or under medical treatment.
2. Subject who is under exercise therapy or dietetic therapy.
3. Subject who has an allergy for test food.
4. Subject who has or had a history of either medicine or alcohol dependence syndrome.
5. Subject who has or had a history of mental illness (depression) or sleep disturbance.
6. Subject who is on a night-shift or is a shift worker.
7. Subject whose lifestyle is extremely irregular.
8. Subject who has an unbalanced diet.
9. Subject who has or had a history of disease in liver, kidney, cardiovascular system, gastrointestinal, lung, blood or metabolic function.
10. Subject who has or had a history of eye disease (Not include minor eye diseases).
11. Subject who can stop taking any kind of health food, supplement or medicine other than the test foods during the current study.
12. Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
13. Subject who has blood drawn 200mL within the past 1 months or 400mL within the past 3 months from the day of the consent acquisition.
14. Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
15. Subject who can't keep the daily records.
16. Subject who is judged as an inappropriate candidate according to the screening data.
17. Subject who is considered as an inappropriate candidate by the doctor in charge.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kei Yui

Organization

FANCL Corporation

Division name

Research Institute, Health science research center

Zip code


Address

12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa

TEL

045-820-3755

Email

ke-yui@fancl.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masao Matsuoka

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code


Address

Round Cross Tamachi. 10th Fl., 5-31-19 Shiba,Minato-ku,108-0014,Japan

TEL

03-3431-1260

Homepage URL


Email

matsuoka@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

FANCL Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療社団法人 幸野メディカルクリニック


Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 02 Month 01 Day

Date of IRB

2019 Year 02 Month 01 Day

Anticipated trial start date

2019 Year 02 Month 04 Day

Last follow-up date

2019 Year 04 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 02 Month 04 Day

Last modified on

2020 Year 02 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040717


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name